Action Seeking Judgment of Compliance with FRAND Obligations Survives Only Insofar as it Relates to U.S. Patent Rights

Mar 11, 2020

Reading Time : 2 min

Under the applicable regional circuit law, before exercising jurisdiction in a declaratory judgment action, a district court must decide (1) whether an “actual controversy” exists between the parties; (2) whether it has authority to grant declaratory relief; and (3) whether to exercise its broad discretion to decide or dismiss a declaratory judgment action. Moreover, when assessing a Rule 12(b)(1) motion, “the district court is to accept as true the allegations and facts set forth in the complaint.”

Optis’ complaint alleged that it engaged in “good faith efforts to license [its] essential patents to Apple on FRAND terms” but that “Apple ha[d] not reciprocated [those] efforts.” Optis accordingly requested declaratory judgment that: (1) Optis’ efforts complied with the Intellectual Property Rights Policy of the European Telecommunications Standards Institute; (2) the efforts “were consistent with competition law requirements”; (3) Optis had “no US liability based on [its] conduct”; and (4) Apple “may no longer raise a FRAND defense in the US.”

In its motion to dismiss, Apple argued that “the [c]ourt did not have or should decline jurisdiction over [Optis’] claim as it relates to foreign patents.” Optis further argued that, as such, there would be no “actual controversy” set forth in the complaint because the alleged licensing efforts all included foreign patents and thus “any determination of whether a hypothetical offer for a U.S.-only license complied with FRAND obligations would be an [improper] advisory opinion.”

Judge Gilstrap agreed with Apple’s first argument and concluded that “foreign obligations under foreign laws related to foreign patents are best left to the courts of those foreign countries.” But he disagreed that there was no “actual controversy” simply because the alleged licensing offers all included foreign patents. According to the court, a patentee need not “make individual license offers for standard essential patents in each country in order to be deemed to have complied with its FRAND and other obligations in that country.” And “while a global license would involve foreign patents subject to foreign FRAND obligations, [it] would also involve U.S. patents subject to U.S. FRAND and anti-competition obligations.” As Judge Gilstrap explained, the U.S. components of the license could conceivably be “extricated” from the foreign components, and Optis should not be denied the opportunity to make such a showing.

To support its motion, Apple relied heavily on a prior case in which Judge Gilstrap dismissed both foreign and U.S. claims when a party sought judgment of FRAND compliance based on a “worldwide” licensing offer. See Optis Wireless Technology, LLC v. Huawei Technologies Co., No. 2:17-CV-00123-JRG-RSP, 2018 WL 3375192 (E.D. Tex. July 11, 2018). Judge Gilstrap determined that Huawei was distinguishable because of its “very different procedural posture.” In Huawei, dismissal occurred “after a bench trial in which [the plaintiffs] failed to present any evidence that they had offered a license to U.S.-only patents.” The plaintiffs’ expert in Huawei “testified that he ha[d] offered no opinions as to whether there was FRAND compliance by [the plaintiff] with respect to only U.S. patents.” According to Judge Gilstrap, “such a failure of proof in the Huawei case should not preclude [Optis] from attempting to offer such proof in this case.”

Practice Tip: Parties involved in foreign litigation related to the licensing of SEPs under FRAND terms must recognize the effects of foreign actions and foreign licensing activities on U.S. litigation. Jurisdiction and eventual judgment in the U.S. hinges on allegations and evidence that is tied to U.S. patent rights.

Optis Wireless Technology, LLC et al v. Apple Inc., 2:19-cv-00066-JRG (E.D. Tex. Mar. 2, 2020) (Gilstrap, J.)

Share This Insight

Previous Entries

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to invalidate claims in district court.

...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.

...

Read More

IP Newsflash

April 1, 2025

The District of Delaware recently denied in part a motion to compel production of documents and testimony between a patentee and potential investors, valuation firms and an international bank based on the common interest exception. In so doing, the court reaffirmed that disclosure of privileged information to third parties will generally waive privilege unless it can be shown that the parties’ interests are identical and the communications are legal, not solely commercial.

...

Read More

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.